Lee Fidler1, Irena Doubelt2, Sonja Kandel3, Jolene H Fisher4, Shikha Mittoo5, Shane Shapera4. 1. Department of Medicine, Division of Respirology, University Health Network, University of Toronto, Toronto, Canada. lee.fidler@utoronto.ca. 2. Department of Medicine, University of Toronto, Toronto, Canada. 3. Department of Medicine, Department of Radiology, University Health Network, Toronto, Canada. 4. Department of Medicine, Division of Respirology, University Health Network, University of Toronto, Toronto, Canada. 5. Division of Rheumatology, University Health Network, Toronto, ON, Canada.
Abstract
PURPOSE: International guidelines recommend screening for connective tissue disease (CTD) with autoantibodies when evaluating patients with idiopathic interstitial lung disease (ILD). Idiopathic inflammatory myositis comprises of a subgroup of CTD diagnosed with myositis antibodies (MA), often presenting with ILD. Our aim was to evaluate the utility of MA screening in patients with idiopathic ILD. METHODS: A retrospective analysis was conducted on patients referred with idiopathic ILD to a tertiary centre ILD clinic who were screened for MA. Patients with known or suspected CTD were excluded. Descriptive statistics, univariate analysis and multivariable logistic regression were used to detect associations between MA and patient characteristics. RESULTS: Of 360 patients, 165 met inclusion criteria and 44 (26.7%) were identified to have MA. Fourteen patients (8.5%) had a change in diagnosis as a result of MA screening. Multivariable logistic regression identified the presence of MA to be associated with current smoking [OR 6.87 (1.65-28.64), p = 0.008] and a diffusing capacity of < 70% predicted [OR 2.55 (1.09-5.97), p = 0.03]. In patients with a change in diagnosis due to MA screening, 3 (1.8%) underwent a surgical lung biopsy and 2 (1.2%) were previously treated with antifibrotic therapy. CONCLUSIONS: Screening for MA in patients with idiopathic ILD can contribute to a change in patient diagnosis, and may prevent invasive testing and unproven use of antifibrotic therapy. These results support the addition of MA to CTD screening panels during the initial evaluation of idiopathic ILD.
PURPOSE: International guidelines recommend screening for connective tissue disease (CTD) with autoantibodies when evaluating patients with idiopathic interstitial lung disease (ILD). Idiopathic inflammatory myositis comprises of a subgroup of CTD diagnosed with myositis antibodies (MA), often presenting with ILD. Our aim was to evaluate the utility of MA screening in patients with idiopathic ILD. METHODS: A retrospective analysis was conducted on patients referred with idiopathic ILD to a tertiary centre ILD clinic who were screened for MA. Patients with known or suspected CTD were excluded. Descriptive statistics, univariate analysis and multivariable logistic regression were used to detect associations between MA and patient characteristics. RESULTS: Of 360 patients, 165 met inclusion criteria and 44 (26.7%) were identified to have MA. Fourteen patients (8.5%) had a change in diagnosis as a result of MA screening. Multivariable logistic regression identified the presence of MA to be associated with current smoking [OR 6.87 (1.65-28.64), p = 0.008] and a diffusing capacity of < 70% predicted [OR 2.55 (1.09-5.97), p = 0.03]. In patients with a change in diagnosis due to MA screening, 3 (1.8%) underwent a surgical lung biopsy and 2 (1.2%) were previously treated with antifibrotic therapy. CONCLUSIONS: Screening for MA in patients with idiopathic ILD can contribute to a change in patient diagnosis, and may prevent invasive testing and unproven use of antifibrotic therapy. These results support the addition of MA to CTD screening panels during the initial evaluation of idiopathic ILD.
Authors: John P Hutchinson; Andrew W Fogarty; Tricia M McKeever; Richard B Hubbard Journal: Am J Respir Crit Care Med Date: 2016-05-15 Impact factor: 21.405
Authors: Jeong-Hwa Hwang; Shigeki Misumi; Hakan Sahin; Kevin K Brown; John D Newell; David A Lynch Journal: J Comput Assist Tomogr Date: 2009 May-Jun Impact factor: 1.826
Authors: Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann Journal: Am J Respir Crit Care Med Date: 2011-03-15 Impact factor: 21.405
Authors: Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez Journal: N Engl J Med Date: 2012-05-20 Impact factor: 91.245
Authors: K M Antoniou; G A Margaritopoulos; N S Goh; K Karagiannis; S R Desai; A G Nicholson; N M Siafakas; J G Coghlan; C P Denton; D M Hansell; A U Wells Journal: Arthritis Rheumatol Date: 2016-04 Impact factor: 10.995
Authors: Shikha Mittoo; Allan C Gelber; Lisa Christopher-Stine; Maureen R Horton; Noah Lechtzin; Sonye K Danoff Journal: Respir Med Date: 2009-03-21 Impact factor: 3.415
Authors: Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson Journal: Am J Respir Crit Care Med Date: 2018-09-01 Impact factor: 21.405
Authors: Mithu Maheswaranathan; Andrew Johannemann; Jason J Weiner; Ryan Jessee; Amanda M Eudy; Lisa Criscione-Schreiber Journal: Clin Rheumatol Date: 2021-02-24 Impact factor: 2.980
Authors: Sofia A Moll; Mark G J P Platenburg; Anouk C M Platteel; Adriane D M Vorselaars; Montse Janssen Bonàs; Claudia Roodenburg-Benschop; Bob Meek; Coline H M van Moorsel; Jan C Grutters Journal: J Clin Med Date: 2020-09-11 Impact factor: 4.241